Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for tough prostate cancer: experimental drug takes on standard treatments

NCT ID NCT06136624

Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Sep 04, 2026 · Updated 7 times

Summary

This large Phase 3 trial is testing a new oral drug called opevesostat (MK-5684) against two standard drugs (abiraterone or enzalutamide) in men with metastatic castration-resistant prostate cancer that has worsened after prior hormone therapy and chemotherapy. The study aims to see if opevesostat helps patients live longer. About 1,310 men will participate at multiple sites.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Opevesostat (MK-5684)
What this could lead to
If successful, this could offer a new treatment option for men with advanced prostate cancer that has stopped responding to standard hormone therapy and chemotherapy.
What could go wrong
This is an early-stage Phase 3 trial, so results are not yet known. The new drug may not improve survival or could have side effects that outweigh benefits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 1,310 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2023

Expected to finish

Feb 2030

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Has histologically- or cytologically-confirmed adenocarcinoma of the prostate without small cell histology. * Has prostate cancer progression while on androgen deprivation therapy (or post bilateral orchiectomy) within 6 months before Screening * Has current evidence of distant metastatic disease (M1 disease) documented by either bone lesions on bone scan and/or soft tissue disease by computed tomography/magnetic resonance imaging (CT/MRI). * Has disease that progressed during or after treatment with 1 novel hormonal agent (NHA) * Has received 1 but no more than 2 taxane-based chemotherapy regimens for metastatic castration-resistant prostate cancer (mCRPC) and has had progressive disease (PD) during or after treatment * Has ongoing androgen deprivation with serum testosterone \<50 ng/dL (\<1.7 nM) * Has provided tumor tissue from a fresh core or excisional biopsy from soft tissue not previously irradiated * Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 assessed within 7 days of randomization * Has had prior treatment with PARPi or were deemed ineligible to receive treatment by the investigator or have refused PARPi treatment * Has received prior 177Lu-PSMA-617 or were deemed ineligible to receive 177Lu-PSMA-617 treatment by the investigator or refused 177Lu-PSMA-617 treatment * Participants who have not received cabazitaxel can be enrolled if they are ineligible for cabazitaxel treatment as determined by the investigator or have refused treatment * If participant received first generation anti-androgen therapy before screening, the participant has evidence of disease progression \>4 weeks since the last flutamide treatment and \>6 weeks since the last bicalutamide or nilutamide treatment * Participants receiving bone resorptive therapy (including, but not limited to, bisphosphonate or denosumab) must have been on stable doses for ≥ 4 weeks before the date of randomization * Participants with human immunodeficiency virus (HIV) infection must have well controlled HIV on antiretroviral therapy (ART) * Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load before randomization * Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at Screening. * Participants who can produce sperm must agree to the following during the study treatment period and for at least 7 days after the last dose of opevesostat, for at least 30 days after the last dose of abiraterone acetate, and for at least 3 months after the last dose of enzalutamide: EITHER be abstinent OR must agree to use male condom Exclusion Criteria: * Has a gastrointestinal disorder that might affect absorption * Has a history of pituitary dysfunction * Has poorly controlled diabetes mellitus * Has clinically significant abnormal serum potassium or sodium level * Has a history of active or unstable cardio/cerebro-vascular disease, including thromboembolic events * Has a history of seizure within 6 months of providing documented informed consent or any condition that may predispose to seizures within 12 months before the date of randomization * Has a history of clinically significant ventricular arrhythmias * Has received an anticancer monoclonal antibody (mAb) within 4 weeks before the date of randomization, or has not recovered from adverse events (AEs) due to mAbs administered more than 4 weeks before the date of randomization * Has undergone major surgery, including local prostate intervention (except prostate biopsy), within 28 days before the date of randomization, and has not recovered from the toxicities and/or complications * Participants who have not adequately recovered from major surgery or have ongoing surgical complications * Has used herbal or medicinal products that may have hormonal anti-prostate cancer activity and/or are known to decrease prostate-specific Antigen (PSA) (eg, saw palmetto, megesterol acetate, citrus pectin polysaccharide) within 4 weeks before the date of randomization * Has received radium-223 or Lutetium-177 within 4 weeks before the date of randomization, or has not recovered to Grade ≤1 or baseline from AEs due to radium-223 or Lutetium-177 administered more than 4 weeks before the date of randomization * Has received treatment with 5-αreductase inhibitors (eg, finasteride or dutasteride), estrogens, or cyproterone within 4 weeks before the date of randomization * Has received colony-stimulating factors within 28 days before the date of randomization * Has received a whole blood transfusion in the last 120 days before the date of randomization. Packed red blood cells and platelet transfusions are acceptable if not given within 28 days of the date of randomization * Has received prior targeted small molecule therapy or NHA treatment within 4 weeks before the first dose of study intervention as follows: enzalutamide or apalutamide within 3 weeks or abiraterone acetate + prednisone or darolutamide within 2 weeks * Has a "superscan" bone scan * Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior the first dose of study medication * Has a known additional malignancy that is progressing or has required active treatment within the past 3 years * Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis * Has an active autoimmune disease that has required systemic treatment in past 2 years * Has an active infection requiring systemic therapy * Has concurrent active HBV or known active HCV infection * Has a history of long QTc syndrome * Has any of the following at Screening Visit: hypotension (systolic BP \<110 mm Hg) or uncontrolled hypertension (systolic BP ≥160 mm Hg or diastolic BP ≥90 mm Hg, in 2 out of 3 recordings with optimized antihypertensive therapy) * Is unable to swallow capsules/tablets * Is currently being treated with cytochrome 450-inducing antiepileptic drugs for seizures * Participants on an unstable dose of thyroid hormone therapy within 6 months before the start of the study intervention * Received prior systemic anticancer therapy including investigational agents within 4 weeks before the first dose of study intervention * Received prior radiotherapy within 2 weeks of start of study intervention, or radiation-related toxicities, requiring corticosteroids * Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention * Systemic use of the following medications within 2 weeks before the first dose of study intervention: strong CYP3A4 inducers (eg, avasimibe, carbamazepine, lumacaftor, phenobarbital, rifampicin, rifapentine, or St John's Wort); P-gp inhibitors (eg, erythromycin, clarithromycin, rifampicin, ketoconazole, itraconazole, posaconazole, artesunate-pyronaridine, ritonavir, indinavir, nelfinavir, atazanavir, glecaprevir-pibrentasvir, simeprevir, ledipasvir-sofosbuvir, verapamil, diltiazem, dronedarone, propafenone, quinidine, cyclosporine, valspodar, or milk thistle \[Silybum marianum\]) * Use of aldosterone antagonist (eg, spironolactone, eplerenone) and phenytoin within 4 weeks before the start of the study intervention

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metastatic castration resistant prostate cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Prostate cancer metastatic

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    237 sites in 34 countries. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • A. C. Camargo Cancer Center ( Site 0310)

    ACTIVE_NOT_RECRUITING

    São Paulo, São Paulo, 01509-010, Brazil

  • AHN Allegheny General Hospital ( Site 0001)

    COMPLETED

    Pittsburgh, Pennsylvania, 15212, United States

  • Ad-Vance Medical Research-Research ( Site 1353)

    ACTIVE_NOT_RECRUITING

    Ponce, 00717, Puerto Rico

  • Addenbrooke's Hospital ( Site 1605)

    RECRUITING

    Cambridge, Cambridgeshire, CB2 2QQ, United Kingdom

  • Affiliated hospital of Jiangnan university ( Site 0434)

    RECRUITING

    Wuxi, Jiangsu, 214122, China

  • Akademiska sjukhuset-Blod- och tumörsjukdomar ( Site 1477)

    RECRUITING

    Uppsala, Uppsala County, 751 85, Sweden

  • Akershus Universitetssykehus-Onkologisk avdeling ( Site 1227)

    RECRUITING

    Lørenskog, Akershus, 1474, Norway

  • Akita University Hospital ( Site 0904)

    RECRUITING

    Akita, 010-8543, Japan

  • Aliada-Oncologìa ( Site 1257)

    ACTIVE_NOT_RECRUITING

    Lima, 15036, Peru

  • Amsterdam UMC, locatie VUmc ( Site 1156)

    COMPLETED

    Amsterdam, North Holland, 1081 HV, Netherlands

  • Ankara Bilkent Şehir Hastanesi-Medical Oncology ( Site 1552)

    RECRUITING

    Ankara, 06800, Turkey (Türkiye)

  • Anschutz Cancer Pavilion ( Site 0046)

    RECRUITING

    Aurora, Colorado, 80045, United States

  • Asahikawa Medical University Hospital ( Site 0901)

    RECRUITING

    Asahikawa, Hokkaido, 078-8510, Japan

  • Asan Medical Center-Oncology ( Site 1402)

    RECRUITING

    Songpagu, Seoul, 05505, South Korea

  • Asociación de Beneficencia Hospital Sirio Libanés ( Site 0205)

    RECRUITING

    Buenos Aires, Buenos Aires F.D., C1419AHN, Argentina

  • Atlantic Health System Morristown Medical Center ( Site 0115)

    RECRUITING

    Morristown, New Jersey, 07960, United States

  • Avera Cancer Institute - Aberdeen ( Site 0123)

    RECRUITING

    Aberdeen, South Dakota, 57401, United States

  • Avera Cancer Institute - Marshall ( Site 0122)

    RECRUITING

    Marshall, Minnesota, 56258, United States

  • Avera Cancer Institute - Mitchell ( Site 0121)

    RECRUITING

    Mitchell, South Dakota, 57301, United States

  • Avera Cancer Institute - Pierre ( Site 0118)

    RECRUITING

    Pierre, South Dakota, 57501, United States

  • Avera Cancer Institute - Yankton ( Site 0117)

    RECRUITING

    Yankton, South Dakota, 57078, United States

  • Avera Cancer Institute- Research ( Site 0094)

    RECRUITING

    Sioux Falls, South Dakota, 57105, United States

  • Bacs-Kiskun Varmegyei Oktatokorhaz-Onkoradiologiai Kozpont ( Site 0752)

    RECRUITING

    Kecskemét, Bács-Kiskun county, 6000, Hungary

  • Baltimore Veterans Affairs Medical Center ( Site 0069)

    RECRUITING

    Baltimore, Maryland, 21201, United States

  • Baskent University Dr. Turgut Noyan Research and Training Center-ONCOLOGY ( Site 1554)

    RECRUITING

    Adana, 01250, Turkey (Türkiye)

  • Beijing Cancer hospital-Urinary Surgery ( Site 0395)

    RECRUITING

    Beijing, Beijing Municipality, 100142, China

  • Beijing Friendship Hospital Affiliate of Capital University ( Site 0396)

    RECRUITING

    Beijing, Beijing Municipality, 100050, China

  • Bell Land General Hospital ( Site 0913)

    RECRUITING

    Sakai, Osaka, 599-8247, Japan

  • Blue Ridge Cancer Care ( Site 0004)

    RECRUITING

    Roanoke, Virginia, 24014, United States

  • Bradford Hill Norte ( Site 0357)

    RECRUITING

    Antofagasta, 1240000, Chile

  • Bradfordhill-Clinical Area ( Site 0351)

    RECRUITING

    Santiago, Region M. de Santiago, 8420383, Chile

  • Bruce W. Carter Veterans Affairs Medical Center ( Site 0082)

    COMPLETED

    Miami, Florida, 33125, United States

  • CIO - Centro de Inmuno-Oncología de Occidente ( Site 1103)

    RECRUITING

    Guadalajara, Jalisco, 44630, Mexico

  • Centre Eugène Marquis Rennes - Centre de Lutte Contre le Cancer ( Site 0632)

    RECRUITING

    Rennes, Ille-et-Vilaine, 35042, France

  • Centre Hospitalier Universitaire de Nîmes - Institut de Cancérologie du Gard - Hôpital Universitaire ( Site 0630)

    RECRUITING

    Nîmes, Gard, 30029, France

  • Centre Hospitalier de l'Université de Montréal ( Site 0326)

    ACTIVE_NOT_RECRUITING

    Montreal, Quebec, H2X 3E4, Canada

  • Centre Hospitalier de la Cote Basque ( Site 0633)

    RECRUITING

    Bayonne, Pyrenees-Atlantiques, 64109, France

  • Centre Intégré de Santé et de Services Sociaux de la Montérégie-Centre ( Site 0328)

    RECRUITING

    Greenfield Park, Quebec, J4V 2H1, Canada

  • Centre Jean Perrin - Centre Régional de Lutte contre le Cancer d'Auvergne ( Site 0629)

    RECRUITING

    Clermont-Ferrand, Puy-de-Dome, 63003, France

  • Centre Oscar Lambret ( Site 0634)

    RECRUITING

    Lille, Ain, 59020, France

  • Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0327)

    RECRUITING

    Québec, Quebec, G1J 1Z4, Canada

  • Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Univer ( Site 0329)

    ACTIVE_NOT_RECRUITING

    Sherbrooke, Quebec, J1H 5H4, Canada

  • Centro de Investigacion Clinica de Oaxaca ( Site 1109)

    RECRUITING

    Mexico City, Mexico City, 68020, Mexico

  • Centrum Onkologii im. Prof. Franciszka Lukaszczyka ( Site 1302)

    RECRUITING

    Bydgoszcz, Kuyavian-Pomeranian Voivodeship, 85-796, Poland

  • Chang Gung Medical Foundation-Linkou Branch-Medical Oncology ( Site 1504)

    RECRUITING

    Taoyuan, 333, Taiwan

  • Charing Cross Hospital-Oncology Research ( Site 1606)

    RECRUITING

    London, Hammersmith and Fulham, W6 8RF, United Kingdom

  • Charité Universitaetsmedizin Berlin - Campus Mitte ( Site 0679)

    RECRUITING

    Berlin, 10117, Germany

  • China Medical University Hospital-Department of Urology ( Site 1503)

    RECRUITING

    Taichung, 40447, Taiwan

  • Chongqing Three Gorges Central Hospital's ( Site 0426)

    RECRUITING

    Chongqing, Chongqing Municipality, 404100, China

  • Chongqing University Cancer Hospital ( Site 0416)

    RECRUITING

    Chongqing, Chongqing Municipality, 400030, China

  • Chulalongkorn University ( Site 1530)

    RECRUITING

    Bangkok, Bangkok, 10330, Thailand

  • Clinica Colsanitas S.A, Sede Clínica Universitaria Colombia-Center Investigator ( Site 0501)

    RECRUITING

    Bogotá, Bogota D.C., 111321, Colombia

  • Clinica Universidad Catolica del Maule-Oncology ( Site 0355)

    RECRUITING

    Talca, Maule Region, 3465584, Chile

  • Clinical Research Chile SpA ( Site 0358)

    ACTIVE_NOT_RECRUITING

    Valdivia, Los Ríos Region, 5110683, Chile

  • Clínica Imbanaco S.A.S ( Site 0509)

    COMPLETED

    Cali, Valle del Cauca Department, 760042, Colombia

  • Clínica Sánchez Ferrer ( Site 1261)

    RECRUITING

    Trujillo, La Libertad, 13009, Peru

  • Clínica de Neoplasias Litoral ( Site 0305)

    RECRUITING

    Itajaí, Santa Catarina, 88301-220, Brazil

  • Colorado Clinical Research ( Site 0067)

    COMPLETED

    Lakewood, Colorado, 80228, United States

  • Complexo Hospitalario Universitario de Ourense ( Site 1426)

    RECRUITING

    Ourense, Orense, 32005, Spain

  • Comprehensive Cancer Centers of Nevada ( Site 0010)

    RECRUITING

    Las Vegas, Nevada, 89148, United States

  • Cross Cancer Institute ( Site 0332)

    RECRUITING

    Edmonton, Alberta, T6G 1Z2, Canada

  • Debreceni Egyetem Klinikai Kozpont-Onkológiai Klinika ( Site 0758)

    RECRUITING

    Debrecen, 4032, Hungary

  • Dubbo Hospital ( Site 0235)

    RECRUITING

    Dubbo, New South Wales, 2830, Australia

  • Dunedin Hospital-Southern Blood and Cancers Service ( Site 1203)

    RECRUITING

    Dunedin, Otago, 9016, New Zealand

  • ETZ Elisabeth-Internal Medicine ( Site 1160)

    RECRUITING

    Tilburg, North Brabant, 5022 GC, Netherlands

  • Ehime University Hospital ( Site 0918)

    RECRUITING

    Tōon, Ehime, 791-0295, Japan

  • Emek Medical Center ( Site 0830)

    RECRUITING

    Afula, 1834111, Israel

  • FALP ( Site 0353)

    ACTIVE_NOT_RECRUITING

    Santiago, Region M. de Santiago, 7500921, Chile

  • Faculty of Medicine - Khon Kaen University ( Site 1526)

    RECRUITING

    Muang, Changwat Khon Kaen, 40002, Thailand

  • Faculty of Medicine Siriraj Hospital ( Site 1531)

    RECRUITING

    Bangkoknoi, Bangkok, 10700, Thailand

  • Fakultni nemocnice Olomouc-Onkologicka klinika ( Site 0555)

    RECRUITING

    Olomouc, Olomouc Region, 779 00, Czechia

  • Fakultni nemocnice Ostrava-Klinika onkologicka ( Site 0554)

    RECRUITING

    Ostrava, Moravian-Silesian Region, 708 52, Czechia

  • Fakultni nemocnice v Motole-Onkologicka klinika 2. LF UK a FN Motol ( Site 0551)

    RECRUITING

    Prague, Praha 5, 150 06, Czechia

  • Filios Alta Medicina ( Site 1106)

    RECRUITING

    Monterrey, Nuevo León, 64460, Mexico

  • First Huai'an Hospital Affiliated to Nanjing Medical University ( Site 0436)

    RECRUITING

    Huaian, Jiangsu, 223300, China

  • Florida Cancer Specialists - South ( Site 7003)

    COMPLETED

    Fort Myers, Florida, 33901, United States

  • Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 0877)

    RECRUITING

    Milan, Lombardy, 20133, Italy

  • Franciscus Gasthuis & Vlietland, Locatie Vlietland ( Site 1151)

    RECRUITING

    Schiedam, South Holland, 3118 JH, Netherlands

  • Fred Hutchinson Cancer Center ( Site 0013)

    RECRUITING

    Seattle, Washington, 98109, United States

  • Fudan University Shanghai Cancer Center-Urology department ( Site 0376)

    RECRUITING

    Shanghai, Shanghai Municipality, 200000, China

  • Fukushima Medical University Hospital ( Site 0933)

    RECRUITING

    Fukushima, 960-1295, Japan

  • Fundacion Centro Oncologico de Integración Regional-Medical Oncology ( Site 0204)

    RECRUITING

    Mendoza, M5500AYB, Argentina

  • Fundación Cardiovascular de Colombia ( Site 0503)

    RECRUITING

    Piedecuesta, Santander Department, 681017, Colombia

  • Fundación Instituto Valenciano de Oncología-Oncologico ( Site 1430)

    RECRUITING

    Valencia, Valenciana, Comunitat, 46009, Spain

  • Fundación Valle del Lili ( Site 0505)

    RECRUITING

    Cali, Valle del Cauca Department, 760032, Colombia

  • Gifu University Hospital ( Site 0910)

    RECRUITING

    Gifu, 501-1112, Japan

  • Greenebaum Comprehensive Cancer Center ( Site 0049)

    RECRUITING

    Baltimore, Maryland, 21201, United States

  • Gulhane Egitim Arastirma Hastanesi ( Site 1558)

    RECRUITING

    Ankara, 06010, Turkey (Türkiye)

  • Gustave Roussy ( Site 0626)

    RECRUITING

    Villejuif, Val-de-Marne, 94800, France

  • HELIOS Kliniken Schwerin ( Site 0694)

    RECRUITING

    Schwerin, Mecklenburg-Vorpommern, 19055, Germany

  • HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO-Medical Oncology ( Site 1428)

    RECRUITING

    Seville, 41013, Spain

  • Hacettepe Universite Hastaneleri-oncology hospital ( Site 1551)

    RECRUITING

    Ankara, 06230, Turkey (Türkiye)

  • Hadassah Medical Center ( Site 0833)

    RECRUITING

    Jerusalem, 9112001, Israel

  • Haga Ziekenhuis locatie Leyweg-Oncology ( Site 1164)

    RECRUITING

    The Hague, South Holland, 2545 AA, Netherlands

  • Hattiesburg Clinic Hematology/Oncology ( Site 0120)

    RECRUITING

    Hattiesburg, Mississippi, 39401, United States

  • Henry Ford Hospital ( Site 0015)

    COMPLETED

    Detroit, Michigan, 48202, United States

  • Hiroshima University Hospital ( Site 0916)

    RECRUITING

    Hiroshima, 734-8551, Japan

  • Hokkaido University Hospital ( Site 0931)

    RECRUITING

    Sapporo, Hokkaido, 060-8648, Japan

  • Hopitaux Universitaires de Strasbourg ( Site 0627)

    RECRUITING

    Strasbourg, Bas-Rhin, 67200, France

  • Hospital Aleman-Oncology ( Site 0207)

    ACTIVE_NOT_RECRUITING

    Buenos Aires, C1118AAT, Argentina

  • Hospital Británico de Buenos Aires-Oncology ( Site 0202)

    ACTIVE_NOT_RECRUITING

    Ciudad Autónoma de Buenos Aires, Buenos Aires, C1280AEB, Argentina

  • Hospital Felicio Rocho ( Site 0317)

    RECRUITING

    Belo Horizonte, Minas Gerais, 30110-934, Brazil

  • Hospital Jerez de la Frontera ( Site 1427)

    RECRUITING

    Jerez de la Frontera, Cadiz, 11407, Spain

  • Hospital Kuala Lumpur-Radiotherapy and Oncology ( Site 1078)

    RECRUITING

    Kuala Lumpur, 50586, Malaysia

  • Hospital Lucus Augusti-Oncology ( Site 1432)

    RECRUITING

    Lugo, 27003, Spain

  • Hospital Mario Penna ( Site 0309)

    RECRUITING

    Belo Horizonte, Minas Gerais, 30380-472, Brazil

  • Hospital Santa Rita de Cassia-Centro de Pesquisa Clínica ( Site 0320)

    RECRUITING

    Vitória, Espírito Santo, 29041-295, Brazil

  • Hospital Sultan Ismail ( Site 1081)

    RECRUITING

    Johor Bahru, Johor, 81100, Malaysia

  • Hospital Universitario "Dr. Jose Eleuterio Gonzalez"-Servicio de Oncología ( Site 1107)

    RECRUITING

    Monterrey, Nuevo León, 64460, Mexico

  • Hospital Universitario 12 de Octubre-Medical Oncology ( Site 1433)

    RECRUITING

    Madrid, Madrid, Comunidad de, 28041, Spain

  • Hospital Universitario Ramón y Cajal-Medical Oncology ( Site 1431)

    RECRUITING

    Madrid, Madrid, Comunidad de, 28034, Spain

  • Hospital Universitário Evangélico Mackenzie-Centro de Oncologia Mackenzie ( Site 0314)

    RECRUITING

    Curitiba, Paraná, 80440-220, Brazil

  • Hospital Universitário São Francisco de Assis - Bragança Paulista ( Site 0308)

    RECRUITING

    Bragança Paulista, São Paulo, 12916-542, Brazil

  • Hospital of the University of Occupational and Environmental Health, Japan ( Site 0921)

    COMPLETED

    Kitakyushu, Fukuoka, 807-8556, Japan

  • Huadong Hospital Affiliated to Fudan University-Urology ( Site 0388)

    RECRUITING

    Shanghai, Shanghai Municipality, 200041, China

  • Hubei Cancer Hospital-Urinary surgery ( Site 0406)

    RECRUITING

    Wuhan, Hubei, 430079, China

  • Hunan Cancer Hospital ( Site 0405)

    RECRUITING

    Changsha, Hunan, 410013, China

  • Hôpital Européen Georges Pompidou ( Site 0628)

    ACTIVE_NOT_RECRUITING

    Paris, 75015, France

  • IC La Serena Research ( Site 0356)

    ACTIVE_NOT_RECRUITING

    La Serena, Coquimbo Region, 1720430, Chile

  • IMAT S.A.S ( Site 0504)

    RECRUITING

    Montería, Departamento de Córdoba, 230002, Colombia

  • INSTITUTO NACIONAL DE ENFERMEDADES NEOPLASICAS-Medical Oncology ( Site 1256)

    RECRUITING

    Lima, 15038, Peru

  • IPOR Instituto Peruano de Oncología & Radioterapia-Centro de Investigación ( Site 1254)

    ACTIVE_NOT_RECRUITING

    Lima, 15036, Peru

  • IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori"-Oncologia Medica ( Site 0879)

    RECRUITING

    Meldola, Emilia-Romagna, 47014, Italy

  • Instituto Alexander Fleming-Alexander Fleming ( Site 0206)

    RECRUITING

    Buenos Aires, Buenos Aires F.D., C1426ANZ, Argentina

  • Instituto Regional de Enfermedades Neoplasicas del Centro (IREN CENTRO) ( Site 1258)

    RECRUITING

    Concepción, Departamento de Junín, 12125, Peru

  • Instituto de Investigaciones Clínicas Mar del Plata ( Site 0201)

    ACTIVE_NOT_RECRUITING

    Mar del Plata, Buenos Aires, B7600FZO, Argentina

  • Istanbul Universitesi Cerrahpasa-Medical Oncology ( Site 1555)

    RECRUITING

    Istanbul, 34668, Turkey (Türkiye)

  • James J. Peters VA Medical Center ( Site 0088)

    RECRUITING

    The Bronx, New York, 10468, United States

  • Jiangxi Cancer Hospital ( Site 0386)

    RECRUITING

    Nanchang, Jiangxi, 330029, China

  • Kagawa University Hospital ( Site 0917)

    RECRUITING

    Kita, Kagawa-ken, 761-0701, Japan

  • Kagoshima University Hospital ( Site 0929)

    RECRUITING

    Kagoshima, 890-8520, Japan

  • Kaiser Permanente Riverside Medical Center ( Site 0099)

    RECRUITING

    Riverside, California, 92505, United States

  • Kanazawa Medical University Hospital ( Site 0909)

    RECRUITING

    Mukai-awagasaki, Ishikawa-ken, 920-0265, Japan

  • Kansai Medical University Hospital ( Site 0912)

    RECRUITING

    Hirakata, Osaka, 573-1191, Japan

  • Karolinska Universitetssjukhuset Solna ( Site 1478)

    ACTIVE_NOT_RECRUITING

    Stockholm, Stockholm County, 171 64, Sweden

  • Klinikum Wels-Grieskirchen GmbH ( Site 0279)

    RECRUITING

    Wels, Upper Austria, 4600, Austria

  • Kobe University Hospital ( Site 0914)

    RECRUITING

    Kobe, Hyōgo, 650-0017, Japan

  • Koc Universitesi Hastanesi ( Site 1561)

    RECRUITING

    Istanbul, 34010, Turkey (Türkiye)

  • Kuopion Yliopistollinen Sairaala ( Site 0603)

    ACTIVE_NOT_RECRUITING

    Kuopio, Northern Savonia, 70200, Finland

  • Kurume University Hospital ( Site 0920)

    RECRUITING

    Kurume, Fukuoka, 830-0011, Japan

  • Kyushu University Hospital ( Site 0919)

    RECRUITING

    Fukuoka, 812-8582, Japan

  • M Health Fairview Clinics and Surgery Center ( Site 0019)

    RECRUITING

    Minneapolis, Minnesota, 55455, United States

  • Macquarie University-MQ Health Clinical Trials Unit ( Site 0234)

    RECRUITING

    Macquarie University, New South Wales, 2109, Australia

  • Masarykuv onkologicky ustav-Klinika komplexni onkologicke pece ( Site 0553)

    RECRUITING

    Brno, Brno-mesto, 656 53, Czechia

  • Mazowiecki Szpital Wojewódzki w Siedlcach-Siedleckie Centrum Onkologii ( Site 1310)

    RECRUITING

    Siedlce, Masovian Voivodeship, 08-110, Poland

  • Meander Medisch Centrum ( Site 1157)

    RECRUITING

    Amersfoort, Utrecht, 3813 TZ, Netherlands

  • Medical Care and Research SA de CV ( Site 1108)

    COMPLETED

    Mérida, Yucatán, 97070, Mexico

  • Medical College of Wisconsin ( Site 0020)

    RECRUITING

    Milwaukee, Wisconsin, 53226, United States

  • Medische Centrum Leeuwarden ( Site 1172)

    ACTIVE_NOT_RECRUITING

    Leeuwarden, Provincie Friesland, 8934 AD, Netherlands

  • Medizinische Universität Graz-Innere Medizin Klin. Abt. Onkologie ( Site 0280)

    RECRUITING

    Graz, Styria, 8036, Austria

  • Meir Medical Center. ( Site 0832)

    RECRUITING

    Kfar Saba, 4428164, Israel

  • Memorial Ankara Hastanesi-Medical Oncology ( Site 1557)

    RECRUITING

    Ankara, 06520, Turkey (Türkiye)

  • Metro-Minnesota Community Clinical Oncology ( Site 0014)

    ACTIVE_NOT_RECRUITING

    Saint Louis Park, Minnesota, 55416, United States

  • Miyazaki Prefectural Miyazaki Hospital ( Site 0927)

    RECRUITING

    Miyazaki, 880-8510, Japan

  • Nagano Municipal Hospital ( Site 0932)

    RECRUITING

    Nagano, 381-8551, Japan

  • Nanbu Tokushukai Hospital ( Site 0930)

    RECRUITING

    Shimajiri, Okinawa, 901-0417, Japan

  • Nanchong Central Hospital-urology ( Site 0422)

    RECRUITING

    Nanchong, Sichuan, 500643, China

  • Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School-Urology ( Site 0377)

    RECRUITING

    Nanjing, Jiangsu, 210008, China

  • Nara Medical University Hospital ( Site 0915)

    COMPLETED

    Kashihara, Nara, 634-8522, Japan

  • National Cancer Centre Singapore ( Site 1377)

    RECRUITING

    Singapore, Central Singapore, 168583, Singapore

  • National Cancer Institute ( Site 1079)

    RECRUITING

    Putrajaya, Putrajaya, 62250, Malaysia

  • National Cheng Kung University Hospital-Urology ( Site 1502)

    RECRUITING

    Tainan, 704, Taiwan

  • National Hospital Organization Kumamoto Medical Center ( Site 0924)

    RECRUITING

    Kumamoto, 860-0008, Japan

  • National Hospital Organization Nagasaki Medical Center ( Site 0923)

    RECRUITING

    Ōmura, Nagasaki, 856-8562, Japan

  • National Hospital Organization Oita Medical Center ( Site 0925)

    RECRUITING

    Ōita, 870-0263, Japan

  • National Taiwan University Hospital-Urology ( Site 1506)

    RECRUITING

    Taipei, 10002, Taiwan

  • National University Hospital ( Site 1376)

    RECRUITING

    Singapore, Central Singapore, 119074, Singapore

  • Nederlands Kanker Instituut - Antoni van Leeuwenhoek - NKI-AVL ( Site 1153)

    RECRUITING

    Amsterdam, North Holland, 1066 CX, Netherlands

  • Nograd Varmegyei Szent Lazar Korhaz-Onkologia es Sugarterapias Osztaly ( Site 0761)

    RECRUITING

    Salgótarján, Nógrád megye, 3100, Hungary

  • Obras Sociais Irma Dulce ( Site 0302)

    RECRUITING

    Salvador, Estado de Bahia, 41680-430, Brazil

  • Ochsner Clinic Foundation ( Site 0108)

    COMPLETED

    New Orleans, Louisiana, 70121, United States

  • Odense Universitetshospital-Department of oncology ( Site 0579)

    ACTIVE_NOT_RECRUITING

    Odense, Region Syddanmark, 5000, Denmark

  • Oncosalud-Clinical Research ( Site 1260)

    ACTIVE_NOT_RECRUITING

    Lima, 15036, Peru

  • Ordensklinikum Linz GmbH Elisabethinen-Urologie ( Site 0276)

    RECRUITING

    Linz, Upper Austria, 4020, Austria

  • Oregon Health and Science University ( Site 0028)

    COMPLETED

    Portland, Oregon, 97239, United States

  • Országos Onkológiai Intézet-Urogenitális Tumorok és Klinikai Farmakológiai Osztály ( Site 0756)

    RECRUITING

    Budapest, Pest County, 1122, Hungary

  • Ospedale San Raffaele-Oncologia Medica ( Site 0876)

    RECRUITING

    Milan, 20132, Italy

  • Pan American Center for Oncology Trials - Ciudadela ( Site 1351)

    COMPLETED

    San Juan, 00909, Puerto Rico

  • Peking University First Hospital-Urology ( Site 0390)

    RECRUITING

    Beijing, Beijing Municipality, 100034, China

  • Peter MacCallum Cancer Centre-Parkville Cancer Clinical Trials Unit (PCCTU) ( Site 0230)

    RECRUITING

    Melbourne, Victoria, 3000, Australia

  • Pontificia Universidad Catolica de Chile-Hemato-Oncology ( Site 0354)

    RECRUITING

    Santiago, Region M. de Santiago, 8330024, Chile

  • Prince of Wales Hospital ( Site 0730)

    ACTIVE_NOT_RECRUITING

    Shatin, Hong Kong

  • Princess Alexandra Hospital-Cancer Care Serices ( Site 0237)

    RECRUITING

    Brisbane, Queensland, 4102, Australia

  • Princess Margaret Cancer Centre ( Site 0330)

    RECRUITING

    Toronto, Ontario, M5G 2M9, Canada

  • Puerto Rico Medical Research Center LLC ( Site 1354)

    COMPLETED

    Hato Rey, 00917, Puerto Rico

  • Queen Mary Hospital ( Site 0727)

    ACTIVE_NOT_RECRUITING

    Hong Kong, Hong Kong

  • Quemex Medical and Research ( Site 1112)

    RECRUITING

    Mexico City, Mexico City, 14308, Mexico

  • Rabin Medical Center ( Site 0828)

    RECRUITING

    Petah Tikva, 4941492, Israel

  • Radboudumc-Medical Oncology ( Site 1152)

    RECRUITING

    Nijmegen, Gelderland, 6525 GA, Netherlands

  • Ralph H. Johnson VA Health Care System (RHJVAHCS)-Urology ( Site 0083)

    COMPLETED

    Charleston, South Carolina, 29401, United States

  • Rambam Health Care Campus-Oncology Division ( Site 0826)

    RECRUITING

    Haifa, 3109601, Israel

  • Regionalny Szpital Specjalistyczny im. dr. Władyslawa Biegańskiego ( Site 1316)

    COMPLETED

    Grudziądz, Kuyavian-Pomeranian Voivodeship, 86-300, Poland

  • Rigshospitalet ( Site 0576)

    RECRUITING

    Copenhagen, Capital Region, 2100, Denmark

  • Rutgers Cancer Institute of New Jersey ( Site 0033)

    COMPLETED

    New Brunswick, New Jersey, 08903, United States

  • SCRI Oncology Partners ( Site 7000)

    RECRUITING

    Nashville, Tennessee, 37203, United States

  • Saga-Ken Medical Centre Koseikan ( Site 0922)

    RECRUITING

    Saga, Saga-ken, 840-8571, Japan

  • Sahlgrenska Universitetssjukhuset ( Site 1479)

    RECRUITING

    Gothenburg, Västra Götaland County, 413 45, Sweden

  • Samsun Medical Park Hastanesi-medical oncology ( Site 1560)

    RECRUITING

    Samsun, 55200, Turkey (Türkiye)

  • Samsung Medical Center ( Site 1405)

    RECRUITING

    Seoul, 06351, South Korea

  • Sanatorio Parque ( Site 0208)

    RECRUITING

    Rosario, Santa Fe Province, S2000DSV, Argentina

  • Sapporo Medical University Hospital ( Site 0902)

    RECRUITING

    Sapporo, Hokkaido, 060-8543, Japan

  • Sarawak General Hospital-Radiotherapy Unit ( Site 1076)

    RECRUITING

    Kuching, Sarawak, 93586, Malaysia

  • Second Affiliated hospital of Anhui Medical University-Urology ( Site 0408)

    RECRUITING

    Hefei, Anhui, 230000, China

  • Seoul National University Hospital-Oncology ( Site 1401)

    RECRUITING

    Seoul, 03080, South Korea

  • Severance Hospital, Yonsei University Health System-Medical oncology ( Site 1404)

    RECRUITING

    Seoul, 03722, South Korea

  • Sheba Medical Center ( Site 0827)

    RECRUITING

    Ramat Gan, 5265601, Israel

  • Sociedad De Oncología y Hematología Del Cesar SAS-Oncology ( Site 0502)

    RECRUITING

    Valledupar, Cesar Department, 200001, Colombia

  • Songklanagarind hospital ( Site 1527)

    RECRUITING

    Hat Yai, Changwat Songkhla, 90110, Thailand

  • Southwest Hospital of Third Military Medical University ( Site 0420)

    RECRUITING

    Chongqing, Chongqing Municipality, 400038, China

  • Spaarne Gasthuis - Hoofddorp-Oncology ( Site 1170)

    ACTIVE_NOT_RECRUITING

    Hoofddorp, North Holland, 2134 TM, Netherlands

  • St. Olavs Hospital-Kreftklinikken ( Site 1231)

    ACTIVE_NOT_RECRUITING

    Trondheim, Sor-Trondelag, 7030, Norway

  • St. Vincent's University Hospital ( Site 0802)

    RECRUITING

    Dublin, Dublin, D04 T6F4, Ireland

  • Stanford Cancer Center ( Site 0036)

    RECRUITING

    Palo Alto, California, 94304, United States

  • Suining Central Hospital ( Site 0437)

    RECRUITING

    Suining, Sichuan, 629000, China

  • Sun Yat-sen University Cancer Center-Internal medicine ( Site 0413)

    RECRUITING

    Guangzhou, Guangdong, 511400, China

  • Sunnybrook Research Institute ( Site 0331)

    RECRUITING

    Toronto, Ontario, M4N 3M5, Canada

  • Swietokrzyskie Centrum Onkologii, Samodzielny Publiczny Zakl-Klinika Onkologii Klinicznej, Dzial Ch ( Site 1318)

    RECRUITING

    Kielce, Świętokrzyskie Voivodeship, 25-734, Poland

  • Sykehuset Østfold Kalnes ( Site 1228)

    COMPLETED

    Sarpsborg, Østfold fylke, 1714, Norway

  • Szpital Wojewódzki im. Mikoaja Kopernika w Koszalinie-Oddzial Dzienny Chemioterapii ( Site 1303)

    RECRUITING

    Koszalin, West Pomeranian Voivodeship, 75-581, Poland

  • TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi-oncology ( Site 1553)

    RECRUITING

    Istanbul, 34722, Turkey (Türkiye)

  • Taipei Veterans General Hospital ( Site 1505)

    RECRUITING

    Taipei, 112, Taiwan

  • Tallaght University Hospital ( Site 0801)

    RECRUITING

    Dublin, D24 NR0A, Ireland

  • Tampereen yliopistollinen sairaala ( Site 0604)

    RECRUITING

    Tampere, Pirkanmaa, 33520, Finland

  • Tan Tock Seng Hospital-Medical Oncology ( Site 1378)

    RECRUITING

    Singapore, Central Singapore, 308433, Singapore

  • Tauranga Hospital-Bay of Plenty Clinical Trials Unit ( Site 1201)

    RECRUITING

    Tauranga, Bay of Plenty, 3112, New Zealand

  • Texas Oncology - Central/South Texas ( Site 8003)

    RECRUITING

    Austin, Texas, 78731, United States

  • Texas Oncology - DFW ( Site 8001)

    COMPLETED

    Dallas, Texas, 75246, United States

  • Texas Oncology - Gulf Coast ( Site 8002)

    RECRUITING

    Houston, Texas, 77024, United States

  • The Beatson West of Scotland Cancer Centre ( Site 1603)

    RECRUITING

    Glasgow, Glasgow City, G12 0YN, United Kingdom

  • The Christie NHS Foundation Trust ( Site 1608)

    RECRUITING

    Manchester, m20 4bx, United Kingdom

  • The First Affiliated Hospital Of Fujian Medical University-Urology ( Site 0414)

    RECRUITING

    Fuzhou, Fujian, 350005, China

  • The First Affiliated Hospital of Chongqing Medical University ( Site 0427)

    RECRUITING

    Chongqing, Chongqing Municipality, 400010, China

  • The First Affiliated Hospital of Guangzhou Medical University ( Site 0412)

    RECRUITING

    Guangzhou, Guangdong, 510230, China

  • The First Affiliated Hospital of Ningbo University ( Site 0383)

    RECRUITING

    Ningbo, Zhejiang, 315010, China

  • The First Affiliated Hospital of Wenzhou Medical University-Urology Surgery ( Site 0379)

    RECRUITING

    Wenzhou, Zhejiang, 325000, China

  • The First Affiliated Hospital of Xi'an Jiaotong University-Oncology ( Site 0393)

    RECRUITING

    Xi'an, Shaanxi, 710061, China

  • The First Affiliated hospital of Xiamen University-Urology ( Site 0415)

    RECRUITING

    Xiamen, Fujian, 361003, China

  • The First Hospital of Jiaxing-urology ( Site 0380)

    RECRUITING

    Jiaxing, Zhejiang, 314001, China

  • The Jikei University Hospital ( Site 0907)

    COMPLETED

    Minato, Tokyo, 105-8471, Japan

  • The Ottawa Hospital - General Campus-The Ottawa Hospital Cancer Centre ( Site 0336)

    RECRUITING

    Ottawa, Ontario, K1H 8L6, Canada

  • The Royal Cornwall Hospital ( Site 1610)

    RECRUITING

    Truro, England, TR1 3LJ, United Kingdom

  • The Second Affiliated Hospital Of Kunming Medical University ( Site 0429)

    RECRUITING

    Kunming, Yunnan, 650033, China

  • The Second Affiliated Hospital of Xi'an Jiaotong University ( Site 0394)

    RECRUITING

    Xi'an, Shaanxi, 710004, China

  • The Second Hospital of Tianjin Medical University ( Site 0391)

    RECRUITING

    Tianjin, Tianjin Municipality, 300211, China

  • The Third People's Hospital of Chengdu (CDTPH) ( Site 0428)

    RECRUITING

    Chengdu, Sichuan, 500643, China

  • The University of Osaka Hospital ( Site 0911)

    RECRUITING

    Suita, Osaka, 565-0871, Japan

  • Tianjin Medical University Cancer Institute & Hospital ( Site 0392)

    RECRUITING

    Tianjin, Tianjin Municipality, 300060, China

  • Toho University Sakura Medical Center ( Site 0906)

    RECRUITING

    Sakura, Chiba, 285-8741, Japan

  • Tongji Hospital Tongji Medical,Science & Technology ( Site 0407)

    RECRUITING

    Wuhan, Hubei, 430000, China

  • Turku University Hospital-Department of Oncology ( Site 0601)

    RECRUITING

    Turku, Southwest Finland, 20520, Finland

  • Universitaetsklinikum Hamburg-Eppendorf-Onkologisches Zentrum ( Site 0705)

    RECRUITING

    Hamburg, 20246, Germany

  • University College London Hospital ( Site 1612)

    RECRUITING

    London, London, City of, NW1 2PG, United Kingdom

  • University Hospitals Cleveland Medical Center ( Site 0043)

    RECRUITING

    Cleveland, Ohio, 44106, United States

  • University Malaya Medical Centre ( Site 1077)

    COMPLETED

    Lembah Pantai, Kuala Lumpur, 59100, Malaysia

  • University Of Nebraska Medical Center-Oncology/Hematology ( Site 0095)

    RECRUITING

    Omaha, Nebraska, 68105, United States

  • University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 0040)

    COMPLETED

    Orange, California, 92868, United States

  • University of Chicago Medical Center ( Site 0045)

    RECRUITING

    Chicago, Illinois, 60637, United States

  • University of Colorado Health - Highlands Ranch Hospital ( Site 0111)

    RECRUITING

    Highlands Ranch, Colorado, 80129, United States

  • University of Colorado Health - Lone Tree Medical Center ( Site 0112)

    RECRUITING

    Lone Tree, Colorado, 80124, United States

  • University of Illinois at Chicago ( Site 0105)

    RECRUITING

    Chicago, Illinois, 60612, United States

  • University of Iowa ( Site 0047)

    COMPLETED

    Iowa City, Iowa, 52242, United States

  • University of Kentucky Chandler Medical Center ( Site 0048)

    COMPLETED

    Lexington, Kentucky, 40536, United States

  • University of Miami Hospital and Clinics, Sylvester Cancer Center ( Site 0051)

    RECRUITING

    Miami, Florida, 33136, United States

  • University of Miyazaki Hospital ( Site 0926)

    RECRUITING

    Miyazaki, 889-1692, Japan

  • University of Virginia Health System ( Site 0054)

    RECRUITING

    Charlottesville, Virginia, 22908, United States

  • Universitätsklinikum Bonn-Klinik und Poliklinik für Urologie und Kinderurologie ( Site 0680)

    RECRUITING

    Bonn, North Rhine-Westphalia, 53127, Germany

  • Universitätsklinikum Jena-Klinik und Poliklinik für Urologie ( Site 0682)

    RECRUITING

    Jena, Thuringia, 07747, Germany

  • Universitätsklinikum Münster - Albert Schweitzer Campus-Klinik für Urologie ( Site 0678)

    RECRUITING

    Münster, North Rhine-Westphalia, 48149, Germany

  • Universitätsklinikum Schleswig-Holstein-Klinik für Urologie ( Site 0691)

    RECRUITING

    Lübeck, Schleswig-Holstein, 23538, Germany

  • VA Portland Health Care System ( Site 0058)

    RECRUITING

    Portland, Oregon, 97239, United States

  • VCU Health Adult Outpatient Pavillion ( Site 0061)

    COMPLETED

    Richmond, Virginia, 23219, United States

  • Vejle Sygehus ( Site 0578)

    RECRUITING

    Vejle, Region Syddanmark, 7100, Denmark

  • VieCuri Medisch Centrum ( Site 1173)

    COMPLETED

    Venlo, Limburg, 5912 BL, Netherlands

  • Washington University School of Medicine-Internal Medicine/Oncology ( Site 0062)

    RECRUITING

    St Louis, Missouri, 63110, United States

  • West China Hospital, Sichuan University-Urology Surgery ( Site 0417)

    RECRUITING

    Chengdu, Sichuan, 610041, China

  • Westmead Hospital ( Site 0232)

    RECRUITING

    Westmead, New South Wales, 2145, Australia

  • Wojewodzki Szpital Zespolony im Ludwika Rydygiera w Toruniu ( Site 1304)

    COMPLETED

    Torun, Kuyavian-Pomeranian Voivodeship, 87-100, Poland

  • Xinjiang Medical University Cancer Hospital - Urumqi-Urology ( Site 0419)

    RECRUITING

    Ürümqi, Xinjiang, 830000, China

  • Yale-New Haven Hospital-Yale Cancer Center ( Site 0064)

    RECRUITING

    New Haven, Connecticut, 06510, United States

  • Yantai Yuhuangding Hospital ( Site 0397)

    RECRUITING

    Yantai, Shandong, 264099, China

  • Yokohama City University Medical Center ( Site 0908)

    RECRUITING

    Yokohama, Kanagawa, 232-0024, Japan

  • Yunnan Province Cancer Hospital ( Site 0418)

    RECRUITING

    Kunming, Yunnan, 650107, China

  • Zachodniopomorskie Centrum Onkologii ( Site 1311)

    RECRUITING

    Szczecin, West Pomeranian Voivodeship, 71-730, Poland

  • Zhejiang Cancer Hospital ( Site 0435)

    RECRUITING

    Hangzhou, Zhejiang, 310022, China

  • Zhejiang Provincial People's Hospital-Urology ( Site 0378)

    RECRUITING

    Hangzhou, Zhejiang, 310014, China

  • Zhongshan Hospital Fudan University ( Site 0430)

    RECRUITING

    Shanghai, Shanghai Municipality, 200032, China

  • Zuyderland Medical Centre-Trialbureau Interne Geneeskunde ( Site 1163)

    RECRUITING

    Sittard-Geleen, Limburg, 6162 BG, Netherlands

  • klinikum rechts der isar der technischen universität münchen-Urologische Klinik und Poliklinik ( Site 0696)

    ACTIVE_NOT_RECRUITING

    Munich, Bavaria, 81675, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.